- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Cabaletta Bio Inc(CABA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CABA
11/19/2026: CABA (1-star) is currently NOT-A-BUY. Pass it for now.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on developing targeted engineered T-cell therapies for severe autoimmune diseases. Its primary strengths lie in its innovative CARTA and CAAR T platforms and an expanding RESET clinical trial pipeline targeting conditions like lupus and pemphigus vulgaris. The core investment story centers on the potential to achieve deep, durable immune system resets, offering a transformative therapeutic approach where conventional drugs fall short. However, as a pre-revenue company, it faces significant execution, clinical development, and dilution risks. The stock suits high-risk growth investors willing to monitor clinical data readouts and cash runway management.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Cabaletta offers high-growth potential driven by clinical-stage medical innovation in autoimmune cell therapy. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience sharp price movements and volume surges surrounding clinical trial updates and biotech sector momentum. |
| Value investor | Weak fit | The company lacks commercial revenue and earnings, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | Cabaletta pays no dividends and retains all capital for clinical research. |
| Low-risk investor | Weak fit | High clinical development risks and share price volatility make it unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks experience rapid price swings based on trial outcomes and market sentiment. |
| Valuation risk | High | Valuations rely heavily on future clinical milestones rather than present earnings or cash flow. |
| Competition risk (autoimmune cell therapy competition) | High | Numerous well-funded peers are racing to develop similar CAR-T treatments for autoimmune diseases. |
| Business quality | Medium | While supported by innovative scientific platforms, the business remains pre-revenue and unproven commercially. |
| Dividend income | Low / none | No dividends are paid or anticipated as capital is consumed by R&D. |
| Execution risk | High | Success depends entirely on navigating complex clinical trials, manufacturing, and regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 227.59M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 4.7M shares | Beta 3.54 | 52 Weeks Range 0.98 - 4.23 | Updated Date 11/19/2026 |
52 Weeks Range 0.98 - 4.23 | Updated Date 11/19/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.33 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 61.0%
- Active BUY / eligible
- 64 / 105
- 30-Day BUY Count Change
- +16
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 44.7%
- Active BUY / eligible
- 17 / 38
- 30-Day BUY Count Change
- +9
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -73.29% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Therapeutic Development & Future Commercialization | Currently zero commercial product revenue; future revenue is expected to come from commercializing engineered cell therapies like rese-cel and CAAR T products for autoimmune diseases. | Cabaletta is a pre-revenue research stage company; investors are betting on future medical breakthroughs rather than current sales. |
| Strategic Collaborations and Grants | Potential upfront fees, milestone payments, or research grants from academic or pharmaceutical partnerships. | Non-dilutive funding sources can occasionally supplement capital, though equity financing remains primary. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -56.17M | Price to Sales(TTM) - |
Enterprise Value -56.17M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.44 | Shares Outstanding 215.72M | Shares Floating 196.83M |
Shares Outstanding 215.72M | Shares Floating 196.83M | ||
Percent Insiders 0.76 | Percent Institutions 97.04 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

